S&P 500
(0.02%) 5 071.63 points
Dow Jones
(-0.11%) 38 461 points
Nasdaq
(0.10%) 15 713 points
Oil
(-0.01%) $82.80
Gas
(0.73%) $1.665
Gold
(-0.45%) $2 327.90
Silver
(-0.59%) $27.19
Platinum
(-0.40%) $912.10
USD/EUR
(0.03%) $0.935
USD/NOK
(0.14%) $11.00
USD/GBP
(0.03%) $0.803
USD/RUB
(-0.01%) $92.31

Realaus laiko atnaujinimai Sanofi American [SNY]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Drug Manufacturers—General
Upcoming Earnings Alert

Quarter results tomorrow
(bmo 2024-04-25)

Expected move: +/- 1.97%

BUY
71.43%
return 5.71%
SELL
30.00%
return 4.82%
Atnaujinta24 bal. 2024 @ 23:00

-2.26% $ 46.61

PIRKIMAS 226 min ago

@ $46.69

Išleistas: 24 bal. 2024 @ 22:51


Grąža: -0.17%


Ankstesnis signalas: bal. 24 - 20:35


Ankstesnis signalas: Pardavimas


Grąža: -0.16 %

Live Chart Being Loaded With Signals

Commentary (24 bal. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.58% compare to its pairs and should correct upwards.
Profile picture for Sanofi American Depositary Shares (Each repstg one-half of one)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
Šios dienos apimtis 1.66M
Vidutinė apimtis 1.95M
Rinkos kapitalizacija 109.20B
EPS $0 ( 2024-02-01 )
Kita pelno data ( $0.970 ) 2024-04-25
Last Dividend $1.903 ( 2023-05-30 )
Next Dividend $0 ( N/A )
P/E 20.35
ATR14 $1.020 (2.19%)
Koreliacija (AI algo v.1.1b): Undervalued: 0.58% $46.83 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.27 (neutral)
Trumpas: -0.80 (moderate negative)
Signal:(18) Neutral

Sanofi American Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
PPH0.936
PWOD0.93
ACAHU0.925
WLFC0.914
NWFL0.914
EVOP0.913
ROST0.91
SGHT0.909
HZNP0.907
MGI0.907
10 Labiausiai neigiamai susiję koreliacijos
LNSR-0.936
MEDS-0.922
VS-0.919
LHDX-0.915
STRC-0.912
TIL-0.911
QLGN-0.91
ULBI-0.91
PLMR-0.909
SG-0.909

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sanofi American Koreliacija - Valiuta/Žaliavos

The country flag 0.14
( neutral )
The country flag -0.03
( neutral )
The country flag 0.00
( neutral )
The country flag 0.02
( neutral )
The country flag 0.69
( moderate )
The country flag -0.58
( weak negative )

Sanofi American Finansinės ataskaitos

Annual 2023
Pajamos: $43.07B
Bruto pelnas: $26.50B (61.52 %)
EPS: $4.31
Q4 2023
Pajamos: $22.88B
Bruto pelnas: $14.68B (64.16 %)
EPS: $1.570
Q3 2023
Pajamos: $12.70B
Bruto pelnas: $8.86B (69.75 %)
EPS: $2.01
Q2 2023
Pajamos: $10.68B
Bruto pelnas: $7.41B (69.41 %)
EPS: $2.74

Financial Reports:

No articles found.

Sanofi American Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$3.28
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Sanofi American Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.30 - Increase likely (45.99%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.462 2003-05-28
Last Dividend $1.903 2023-05-30
Next Dividend $0 N/A
Payout Date 2023-06-23
Next Payout Date N/A
# dividends 24 --
Total Paid Out $33.25 --
Avg. Dividend % Per Year 3.34% --
Score 4.99 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 7.30
Div. Directional Score 9.72 --
Next Divdend (Est)
(2025-02-10)
$1.985 Estimate 3.15 %
Dividend Stability
0.25 Very Poor
Dividend Score
4.99
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2003 $0.462 1.49%
2004 $0.610 1.60%
2005 $0.799 2.01%
2006 $0.912 2.00%
2007 $1.145 2.48%
2008 $1.510 3.31%
2009 $1.419 4.34%
2010 $1.627 3.99%
2011 $1.822 5.55%
2012 $1.756 4.72%
2013 $1.862 3.89%
2014 $1.910 3.69%
2015 $1.618 3.55%
2016 $1.630 3.86%
2017 $1.577 3.84%
2018 $1.861 4.30%
2019 $1.739 4.06%
2020 $1.753 3.46%
2021 $1.906 3.91%
2022 $2.04 4.02%
2023 $3.28 6.69%
2024 $0 0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1391.5007.2310.00[0 - 0.5]
returnOnAssetsTTM0.06271.2007.919.49[0 - 0.3]
returnOnEquityTTM0.1081.5009.9210.00[0.1 - 1]
payoutRatioTTM0.579-1.0004.21-4.21[0 - 1]
currentRatioTTM1.2670.8008.666.93[1 - 3]
quickRatioTTM0.8270.8009.847.87[0.8 - 2.5]
cashRatioTTM0.3601.5009.1110.00[0.2 - 2]
debtRatioTTM0.132-1.5007.80-10.00[0 - 0.6]
interestCoverageTTM9.291.0007.677.67[3 - 30]
operatingCashFlowPerShareTTM8.202.007.2710.00[0 - 30]
freeCashFlowPerShareTTM5.602.007.2010.00[0 - 20]
debtEquityRatioTTM0.225-1.5009.10-10.00[0 - 2.5]
grossProfitMarginTTM0.6781.0002.032.03[0.2 - 0.8]
operatingProfitMarginTTM0.2601.0006.806.80[0.1 - 0.6]
cashFlowToDebtRatioTTM0.6151.0007.697.69[0.2 - 2]
assetTurnoverTTM0.4520.800-0.322-0.258[0.5 - 2]
Total Score12.14

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM14.121.0008.670[1 - 100]
returnOnEquityTTM0.1082.509.9510.00[0.1 - 1.5]
freeCashFlowPerShareTTM5.602.008.1310.00[0 - 30]
dividendYielPercentageTTM3.981.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM8.202.007.2710.00[0 - 30]
payoutRatioTTM0.5791.5004.21-4.21[0 - 1]
pegRatioTTM0.6451.5009.030[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1801.0008.010[0.1 - 0.5]
Total Score7.30

Sanofi American

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.